Chiasma

About

Headcount over time

Offices

Q&A

What is Chiasma's primary focus?

Chiasma was a biopharmaceutical company that developed oral drug products for rare and serious chronic diseases, utilizing its Transient Permeability Enhancer (TPE) technology platform.

When was Chiasma acquired and by whom?

Chiasma was acquired by Amryt Pharma Group in August 2021 for $330,000,000.

What was Chiasma's lead product and its FDA approval status?

Chiasma's lead product, Mycapssa (octreotide) capsules, received FDA approval in June 2020 for the long-term maintenance treatment of acromegaly.

How much capital did Chiasma raise in total before its acquisition?

Chiasma raised a total of $293,700,000 in funding.

When did Chiasma conduct its initial public offering (IPO) and how much did it raise?

Chiasma raised $102,000,000 in its Public Offering in July 2015, with Barclays Capital and Cowen & Co. as lead investors.

Which investors participated in Chiasma's Series E funding round?

In March 2015, Chiasma closed a $70,000,000 Series E funding round with lead investors Rock Springs Capital.

What was a significant debt financing event for Chiasma?

In April 2020, Chiasma secured $75,000,000 in debt financing from HealthCare Royalty Partners.

What is the current employee count for Chiasma?

Chiasma currently has 11-50 employees.

Team · 6

Derek Brown

VP Marketing

Shoshie Katz

VP RA/QA

Gary Patou

Head of Clinical

Mark Fitzpatrick

President and CEO

Raj Kannan

CEO

Anand Varadan

Chief Commercial Officer

Sectors & technology

Highlights

Tags